Literature DB >> 16415231

Estimation of the relative risk of developing clinical scrapie: the role of prion protein (PrP) genotype and selection bias.

S C Tongue1, D U Pfeiffer, R Warner, H Elliott, V Del Rio Vilas.   

Abstract

Prion protein (PrP) genotype data from statutory confirmed cases and from three non-case datasets have been used to calculate the odds ratio (or) for the development of clinical scrapie for an individual sheep of a given PrP genotype, compared with one possessing the "wild-type" ARQ/ARQ genotype. Logistic regression has been used to estimate the ors, and a multiple-test procedure has been used to evaluate the statistical significance of each comparison. The results are similar to those observed in other studies: the VRQ/VRQ genotype has or point estimates greater than 20; the ARQ/VRQ and ARH/VRQ genotypes have or point estimates between 5 and 20; AHQ/VRQ between 0.03 and 0.1; ARR/VRQ 0.4 and 0.5; all the other PrP genotypes, excluding ARR/ARR, ARR/ARH and AHQ/ARH for which no clinical cases have been recorded have or point estimates of less than 0.3. The estimates derived from each dataset are comparable, but not identical. This can be explained by plausible biases inherent in the sampling of the non-case populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415231     DOI: 10.1136/vr.158.2.43

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  22 in total

1.  The importance of the PrP genotype in active surveillance for ovine scrapie.

Authors:  S C Tongue; J W Wilesmith; J Nash; M Kossaibati; J Ryan
Journal:  Epidemiol Infect       Date:  2007-06-25       Impact factor: 2.451

2.  Prions are secreted in milk from clinically normal scrapie-exposed sheep.

Authors:  B C Maddison; C A Baker; H C Rees; L A Terry; L Thorne; S J Bellworthy; G C Whitelam; K C Gough
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

3.  In vitro amplification of prions from milk in the detection of subclinical infections.

Authors:  Kevin C Gough; Claire A Baker; Maged Taema; Ben C Maddison
Journal:  Prion       Date:  2009-10-23       Impact factor: 3.931

4.  Report of outbreaks of classical scrapie in Dorper sheep and associated prion protein gene polymorphisms in affected flocks.

Authors:  Caroline Pinto de Andrade; Eduardo Conceição de Oliveira; Juliano Souza Leal; Laura Lopes de Almeida; Luiza Amaral de Castro; Sergio Ceroni da Silva; David Driemeier
Journal:  Trop Anim Health Prod       Date:  2015-05-21       Impact factor: 1.559

5.  Prevalence of sheep infected with classical scrapie in Great Britain: integrating multiple sources of surveillance data for 2002.

Authors:  Simon Gubbins
Journal:  J R Soc Interface       Date:  2008-11-06       Impact factor: 4.118

Review 6.  The role of mathematical modelling in understanding the epidemiology and control of sheep transmissible spongiform encephalopathies: a review.

Authors:  Simon Gubbins; Suzanne Touzeau; Thomas J Hagenaars
Journal:  Vet Res       Date:  2010-02-23       Impact factor: 3.683

7.  Scrapie prevalence in sheep of susceptible genotype is declining in a population subject to breeding for resistance.

Authors:  Thomas J Hagenaars; Marielle B Melchior; Alex Bossers; Aart Davidse; Bas Engel; Fred G van Zijderveld
Journal:  BMC Vet Res       Date:  2010-05-14       Impact factor: 2.741

8.  Quantifying the risk from ovine BSE and the impact of control strategies.

Authors:  Helen R Fryer; Matthew Baylis; Kumar Sivam; Angela R McLean
Journal:  Proc Biol Sci       Date:  2007-06-22       Impact factor: 5.349

9.  The impact of the genotype on the prevalence of classical scrapie at population level.

Authors:  Angel Ortiz-Pelaez; Juana Bianchini
Journal:  Vet Res       Date:  2011-02-15       Impact factor: 3.683

10.  Second passage of chronic wasting disease of mule deer to sheep by intracranial inoculation compared to classical scrapie.

Authors:  Eric D Cassmann; Rylie D Frese; Justin J Greenlee
Journal:  J Vet Diagn Invest       Date:  2021-05-28       Impact factor: 1.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.